Cita APA

Lücking, U., Scholz, A., Lienau, P., Siemeister, G., Kosemund, D., Bohlmann, R., . . . Brands, M. (2017). Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem.

Chicago Style Citation

Lücking, Ulrich, et al. "Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer." ChemMedChem 2017.

Cita MLA

Lücking, Ulrich, et al. "Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer." ChemMedChem 2017.